Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 98 | 2024 | 5811 | 9.570 |
Why?
|
Carcinoma, Squamous Cell | 54 | 2024 | 4021 | 6.870 |
Why?
|
Carcinoma, Basal Cell | 22 | 2024 | 557 | 6.300 |
Why?
|
Keratosis, Actinic | 9 | 2024 | 72 | 3.840 |
Why?
|
Dermatologic Agents | 8 | 2019 | 313 | 2.170 |
Why?
|
Dermatology | 12 | 2020 | 918 | 2.150 |
Why?
|
Melanoma | 24 | 2023 | 5696 | 1.990 |
Why?
|
Psoriasis | 8 | 2023 | 944 | 1.730 |
Why?
|
California | 22 | 2018 | 1431 | 1.720 |
Why?
|
Keratinocytes | 13 | 2020 | 790 | 1.700 |
Why?
|
Neoplasms, Multiple Primary | 4 | 2019 | 592 | 1.650 |
Why?
|
Dermatitis, Atopic | 6 | 2023 | 731 | 1.560 |
Why?
|
Mohs Surgery | 5 | 2021 | 222 | 1.400 |
Why?
|
Genetic Loci | 6 | 2020 | 2624 | 1.330 |
Why?
|
Vitamin D | 10 | 2021 | 3301 | 1.100 |
Why?
|
Fluorouracil | 5 | 2023 | 1642 | 0.960 |
Why?
|
Genetic Predisposition to Disease | 13 | 2022 | 17878 | 0.830 |
Why?
|
Organ Transplantation | 7 | 2021 | 1157 | 0.830 |
Why?
|
Needs Assessment | 6 | 2018 | 1139 | 0.830 |
Why?
|
Skin Pigmentation | 3 | 2020 | 277 | 0.830 |
Why?
|
Risk Assessment | 21 | 2023 | 23974 | 0.790 |
Why?
|
Sunlight | 4 | 2018 | 337 | 0.740 |
Why?
|
Papillomaviridae | 4 | 2019 | 1117 | 0.730 |
Why?
|
Registries | 8 | 2018 | 8209 | 0.720 |
Why?
|
Biological Products | 3 | 2021 | 912 | 0.710 |
Why?
|
Carcinoma, Merkel Cell | 5 | 2016 | 328 | 0.700 |
Why?
|
Incidence | 23 | 2024 | 21339 | 0.670 |
Why?
|
Health Services Needs and Demand | 3 | 2012 | 1400 | 0.670 |
Why?
|
Humans | 160 | 2024 | 760740 | 0.640 |
Why?
|
Orphan Drug Production | 1 | 2019 | 48 | 0.630 |
Why?
|
Myotonic Dystrophy | 1 | 2019 | 78 | 0.620 |
Why?
|
Women, Working | 1 | 2019 | 86 | 0.620 |
Why?
|
Immunosuppressive Agents | 6 | 2021 | 4172 | 0.590 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2020 | 393 | 0.590 |
Why?
|
Cohort Studies | 30 | 2023 | 41464 | 0.580 |
Why?
|
Aminoquinolines | 1 | 2017 | 106 | 0.580 |
Why?
|
Lentigo | 1 | 2017 | 37 | 0.580 |
Why?
|
Valproic Acid | 1 | 2020 | 443 | 0.570 |
Why?
|
DNA Virus Infections | 1 | 2017 | 15 | 0.570 |
Why?
|
Middle Aged | 68 | 2023 | 220603 | 0.570 |
Why?
|
Risk Factors | 39 | 2024 | 74128 | 0.570 |
Why?
|
Genes, MHC Class II | 1 | 2018 | 433 | 0.570 |
Why?
|
Skin Diseases | 3 | 2023 | 1094 | 0.560 |
Why?
|
Aged | 62 | 2023 | 169092 | 0.550 |
Why?
|
Salaries and Fringe Benefits | 1 | 2019 | 256 | 0.550 |
Why?
|
Hidradenitis Suppurativa | 1 | 2020 | 177 | 0.550 |
Why?
|
SEER Program | 3 | 2017 | 1450 | 0.550 |
Why?
|
Male | 91 | 2024 | 360402 | 0.540 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 5 | 2013 | 2270 | 0.540 |
Why?
|
Dietary Supplements | 5 | 2014 | 3412 | 0.540 |
Why?
|
Polymorphism, Single Nucleotide | 12 | 2024 | 15908 | 0.520 |
Why?
|
Herpes Zoster | 1 | 2018 | 253 | 0.500 |
Why?
|
Female | 89 | 2024 | 392203 | 0.490 |
Why?
|
Mendelian Randomization Analysis | 1 | 2021 | 1007 | 0.490 |
Why?
|
Genome-Wide Association Study | 11 | 2024 | 12661 | 0.490 |
Why?
|
Interferon Regulatory Factors | 1 | 2016 | 261 | 0.490 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2020 | 774 | 0.480 |
Why?
|
Sex Factors | 6 | 2019 | 10549 | 0.470 |
Why?
|
Aged, 80 and over | 30 | 2020 | 58919 | 0.460 |
Why?
|
Managed Care Programs | 3 | 2017 | 937 | 0.460 |
Why?
|
Lithium | 1 | 2017 | 596 | 0.460 |
Why?
|
Epidemiologic Methods | 1 | 2019 | 1335 | 0.460 |
Why?
|
Photosensitizing Agents | 1 | 2018 | 623 | 0.450 |
Why?
|
Patient Care | 1 | 2019 | 621 | 0.450 |
Why?
|
Rare Diseases | 1 | 2019 | 622 | 0.440 |
Why?
|
Evidence-Based Medicine | 3 | 2019 | 3680 | 0.440 |
Why?
|
Antihypertensive Agents | 3 | 2018 | 2018 | 0.440 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2013 | 84 | 0.440 |
Why?
|
Sex Distribution | 6 | 2017 | 2278 | 0.440 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2014 | 101 | 0.430 |
Why?
|
Follow-Up Studies | 17 | 2020 | 39062 | 0.430 |
Why?
|
Physicians, Women | 1 | 2019 | 509 | 0.420 |
Why?
|
Drug Approval | 2 | 2019 | 812 | 0.420 |
Why?
|
Neuroectodermal Tumor, Melanotic | 1 | 2012 | 3 | 0.410 |
Why?
|
Haplotypes | 2 | 2018 | 2713 | 0.410 |
Why?
|
Point-of-Care Systems | 1 | 2021 | 1213 | 0.410 |
Why?
|
Carcinoma, Large Cell | 1 | 2013 | 113 | 0.400 |
Why?
|
Adult | 51 | 2024 | 220995 | 0.400 |
Why?
|
Delivery of Health Care | 4 | 2020 | 5334 | 0.400 |
Why?
|
Community Health Services | 1 | 2017 | 654 | 0.390 |
Why?
|
Retrospective Studies | 30 | 2023 | 80583 | 0.390 |
Why?
|
Carcinoma | 2 | 2020 | 2328 | 0.380 |
Why?
|
Early Detection of Cancer | 3 | 2023 | 3196 | 0.380 |
Why?
|
HLA Antigens | 1 | 2017 | 1327 | 0.380 |
Why?
|
Lymph Node Excision | 2 | 2015 | 1269 | 0.380 |
Why?
|
Glucocorticoids | 1 | 2020 | 2160 | 0.370 |
Why?
|
Membrane Transport Proteins | 1 | 2016 | 1034 | 0.360 |
Why?
|
Vitamins | 5 | 2021 | 1635 | 0.360 |
Why?
|
Vitamin D Deficiency | 3 | 2021 | 1388 | 0.350 |
Why?
|
Pemphigus | 3 | 2024 | 107 | 0.350 |
Why?
|
Arthritis, Psoriatic | 1 | 2013 | 219 | 0.350 |
Why?
|
Skin Aging | 1 | 2011 | 140 | 0.350 |
Why?
|
Epidermis | 1 | 2012 | 526 | 0.340 |
Why?
|
Bacterial Infections | 1 | 2017 | 1389 | 0.320 |
Why?
|
Tea | 1 | 2011 | 287 | 0.320 |
Why?
|
Vitamin A | 1 | 2012 | 612 | 0.320 |
Why?
|
Carotenoids | 1 | 2012 | 621 | 0.320 |
Why?
|
Opioid-Related Disorders | 2 | 2021 | 2164 | 0.310 |
Why?
|
Confidence Intervals | 6 | 2017 | 2925 | 0.310 |
Why?
|
Antigens, Neoplasm | 1 | 2016 | 1985 | 0.310 |
Why?
|
Databases, Factual | 8 | 2019 | 7963 | 0.300 |
Why?
|
Sirolimus | 1 | 2015 | 1533 | 0.300 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2013 | 709 | 0.300 |
Why?
|
Patient Satisfaction | 2 | 2011 | 3451 | 0.300 |
Why?
|
Proportional Hazards Models | 9 | 2017 | 12448 | 0.290 |
Why?
|
Mass Screening | 2 | 2023 | 5425 | 0.290 |
Why?
|
Quality Improvement | 3 | 2020 | 3801 | 0.290 |
Why?
|
Electronic Health Records | 3 | 2021 | 4810 | 0.290 |
Why?
|
Neoplasms, Second Primary | 1 | 2015 | 1051 | 0.290 |
Why?
|
Contraceptives, Oral | 1 | 2010 | 553 | 0.290 |
Why?
|
Models, Statistical | 2 | 2019 | 5074 | 0.290 |
Why?
|
Sunbathing | 2 | 2018 | 65 | 0.280 |
Why?
|
Age Distribution | 4 | 2017 | 2872 | 0.280 |
Why?
|
Epigenesis, Genetic | 1 | 2020 | 3794 | 0.280 |
Why?
|
Young Adult | 19 | 2023 | 59191 | 0.280 |
Why?
|
Population Surveillance | 1 | 2016 | 2597 | 0.260 |
Why?
|
Head Movements | 1 | 2007 | 152 | 0.260 |
Why?
|
Administration, Topical | 2 | 2017 | 703 | 0.250 |
Why?
|
Skin | 6 | 2022 | 4472 | 0.250 |
Why?
|
Research Design | 3 | 2019 | 6174 | 0.250 |
Why?
|
Biomedical Research | 2 | 2019 | 3426 | 0.250 |
Why?
|
Models, Biological | 2 | 2019 | 9461 | 0.240 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2006 | 85 | 0.240 |
Why?
|
Genomics | 2 | 2019 | 5822 | 0.240 |
Why?
|
Analgesics, Opioid | 2 | 2021 | 3805 | 0.240 |
Why?
|
Calcifediol | 2 | 2018 | 161 | 0.240 |
Why?
|
Vaccines | 2 | 2024 | 838 | 0.240 |
Why?
|
Surgery, Plastic | 1 | 2011 | 641 | 0.240 |
Why?
|
Mitochondria | 1 | 2018 | 3619 | 0.240 |
Why?
|
Hemangiosarcoma | 1 | 2007 | 215 | 0.230 |
Why?
|
Quality of Health Care | 1 | 2019 | 4325 | 0.230 |
Why?
|
Kidney Transplantation | 1 | 2019 | 4218 | 0.230 |
Why?
|
Odds Ratio | 7 | 2017 | 9644 | 0.230 |
Why?
|
Prognosis | 13 | 2018 | 29601 | 0.220 |
Why?
|
Risk | 4 | 2019 | 9603 | 0.220 |
Why?
|
Adolescent | 19 | 2023 | 88247 | 0.210 |
Why?
|
United States | 18 | 2023 | 72292 | 0.210 |
Why?
|
Education, Medical, Continuing | 3 | 2019 | 825 | 0.210 |
Why?
|
Disease Susceptibility | 2 | 2020 | 1788 | 0.210 |
Why?
|
Lymph Nodes | 1 | 2014 | 3461 | 0.210 |
Why?
|
Logistic Models | 7 | 2018 | 13248 | 0.210 |
Why?
|
Heterogeneous-Nuclear Ribonucleoprotein Group C | 1 | 2022 | 16 | 0.210 |
Why?
|
Ultraviolet Rays | 4 | 2019 | 1079 | 0.200 |
Why?
|
Patient Participation | 1 | 2011 | 1443 | 0.200 |
Why?
|
Pemphigoid, Bullous | 1 | 2024 | 112 | 0.200 |
Why?
|
Prevalence | 9 | 2024 | 15702 | 0.200 |
Why?
|
DNA, Viral | 2 | 2012 | 2194 | 0.200 |
Why?
|
Morbidity | 3 | 2016 | 1750 | 0.200 |
Why?
|
Enhancer Elements, Genetic | 2 | 2020 | 1360 | 0.200 |
Why?
|
Fibrosarcoma | 1 | 2004 | 308 | 0.200 |
Why?
|
Anticholesteremic Agents | 1 | 2009 | 967 | 0.200 |
Why?
|
United States Food and Drug Administration | 3 | 2019 | 1661 | 0.190 |
Why?
|
Endorphins | 1 | 2021 | 74 | 0.190 |
Why?
|
Molecular Sequence Annotation | 2 | 2020 | 520 | 0.190 |
Why?
|
Antioxidants | 1 | 2009 | 1669 | 0.190 |
Why?
|
Nose | 1 | 2005 | 521 | 0.190 |
Why?
|
Eosinophilia | 1 | 2006 | 559 | 0.190 |
Why?
|
Reference Values | 3 | 2017 | 4919 | 0.180 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2022 | 940 | 0.180 |
Why?
|
Blood Coagulation Disorders | 1 | 2004 | 350 | 0.180 |
Why?
|
Case-Control Studies | 7 | 2023 | 22153 | 0.180 |
Why?
|
Age Factors | 6 | 2018 | 18381 | 0.180 |
Why?
|
Eczema | 1 | 2023 | 246 | 0.170 |
Why?
|
Receptors, Calcitriol | 2 | 2012 | 360 | 0.170 |
Why?
|
Genetic Association Studies | 2 | 2019 | 2734 | 0.170 |
Why?
|
Infant, Premature, Diseases | 1 | 2006 | 710 | 0.170 |
Why?
|
Face | 3 | 2019 | 1026 | 0.170 |
Why?
|
Thymidine Phosphorylase | 1 | 1999 | 14 | 0.170 |
Why?
|
Electronics | 1 | 2021 | 317 | 0.170 |
Why?
|
Xeroderma Pigmentosum | 1 | 2019 | 31 | 0.170 |
Why?
|
Hypertension | 3 | 2018 | 8532 | 0.170 |
Why?
|
Health Maintenance Organizations | 2 | 2014 | 658 | 0.160 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 214 | 0.160 |
Why?
|
Ascorbic Acid | 1 | 2022 | 655 | 0.160 |
Why?
|
Neoplasm Staging | 7 | 2023 | 11118 | 0.160 |
Why?
|
CD4 Lymphocyte Count | 2 | 2017 | 2567 | 0.160 |
Why?
|
Neoplasm Invasiveness | 3 | 2017 | 3593 | 0.160 |
Why?
|
Polymorphism, Genetic | 3 | 2019 | 4242 | 0.160 |
Why?
|
Drug Costs | 2 | 2017 | 1183 | 0.160 |
Why?
|
HIV Infections | 2 | 2017 | 17342 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2023 | 9277 | 0.160 |
Why?
|
Insurance Claim Review | 2 | 2015 | 741 | 0.150 |
Why?
|
Computational Biology | 2 | 2020 | 3509 | 0.150 |
Why?
|
Papillomavirus Infections | 4 | 2019 | 1612 | 0.150 |
Why?
|
Massachusetts | 3 | 2021 | 8835 | 0.150 |
Why?
|
Histocompatibility Testing | 1 | 2019 | 711 | 0.150 |
Why?
|
Photochemotherapy | 2 | 2021 | 823 | 0.150 |
Why?
|
Receptor, Melanocortin, Type 1 | 1 | 2017 | 74 | 0.150 |
Why?
|
Immunocompromised Host | 3 | 2019 | 858 | 0.140 |
Why?
|
Intention to Treat Analysis | 1 | 2018 | 413 | 0.140 |
Why?
|
Head and Neck Neoplasms | 2 | 2014 | 2894 | 0.140 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 1088 | 0.140 |
Why?
|
Comorbidity | 4 | 2018 | 10507 | 0.140 |
Why?
|
Symbiosis | 1 | 2019 | 294 | 0.140 |
Why?
|
Off-Label Use | 1 | 2018 | 185 | 0.140 |
Why?
|
Ultraviolet Therapy | 1 | 2017 | 84 | 0.140 |
Why?
|
Feeding Behavior | 1 | 2009 | 3183 | 0.140 |
Why?
|
Survival Rate | 5 | 2017 | 12719 | 0.140 |
Why?
|
Administration, Cutaneous | 1 | 2018 | 712 | 0.130 |
Why?
|
Injections, Subcutaneous | 1 | 2018 | 671 | 0.130 |
Why?
|
Surgical Flaps | 1 | 2005 | 1670 | 0.130 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2020 | 452 | 0.130 |
Why?
|
Physicians, Primary Care | 2 | 2013 | 618 | 0.130 |
Why?
|
Spondylarthritis | 1 | 2016 | 61 | 0.130 |
Why?
|
Aspergillus | 1 | 2015 | 93 | 0.120 |
Why?
|
Evidence-Based Practice | 1 | 2019 | 494 | 0.120 |
Why?
|
Policy | 1 | 2019 | 506 | 0.120 |
Why?
|
Kava | 1 | 2014 | 2 | 0.120 |
Why?
|
Patient Selection | 3 | 2013 | 4237 | 0.120 |
Why?
|
Rheumatic Diseases | 1 | 2022 | 649 | 0.120 |
Why?
|
Sunburn | 2 | 2018 | 156 | 0.120 |
Why?
|
Spondylitis, Ankylosing | 1 | 2016 | 155 | 0.120 |
Why?
|
Pharmaceutical Services | 1 | 2016 | 141 | 0.120 |
Why?
|
Sebaceous Glands | 1 | 2014 | 42 | 0.120 |
Why?
|
Forkhead Transcription Factors | 1 | 2022 | 1614 | 0.120 |
Why?
|
Causality | 1 | 2021 | 1241 | 0.120 |
Why?
|
Paraneoplastic Syndromes | 1 | 2016 | 155 | 0.120 |
Why?
|
Multifactorial Inheritance | 2 | 2019 | 1381 | 0.120 |
Why?
|
Child, Preschool | 7 | 2018 | 42193 | 0.120 |
Why?
|
Intention | 1 | 2017 | 346 | 0.110 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 3245 | 0.110 |
Why?
|
Plant Preparations | 1 | 2014 | 94 | 0.110 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2017 | 4340 | 0.110 |
Why?
|
Parents | 2 | 2018 | 3563 | 0.110 |
Why?
|
Tumor Virus Infections | 1 | 2016 | 435 | 0.110 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2016 | 348 | 0.110 |
Why?
|
Random Allocation | 1 | 2018 | 2392 | 0.110 |
Why?
|
Genotype | 3 | 2018 | 12977 | 0.110 |
Why?
|
Aspergillosis | 1 | 2015 | 242 | 0.110 |
Why?
|
Extremities | 1 | 2019 | 867 | 0.110 |
Why?
|
Severity of Illness Index | 4 | 2023 | 15829 | 0.110 |
Why?
|
Comparative Effectiveness Research | 1 | 2018 | 708 | 0.110 |
Why?
|
Systematized Nomenclature of Medicine | 1 | 2013 | 34 | 0.110 |
Why?
|
Internet | 2 | 2017 | 3094 | 0.110 |
Why?
|
Disease Progression | 3 | 2020 | 13495 | 0.110 |
Why?
|
Documentation | 1 | 2019 | 896 | 0.110 |
Why?
|
Health Care Surveys | 2 | 2017 | 2422 | 0.110 |
Why?
|
Venous Thrombosis | 1 | 2022 | 1303 | 0.110 |
Why?
|
Head | 1 | 2019 | 922 | 0.110 |
Why?
|
Prospective Studies | 8 | 2018 | 54364 | 0.110 |
Why?
|
Treatment Outcome | 9 | 2023 | 64572 | 0.100 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2017 | 549 | 0.100 |
Why?
|
Lip Neoplasms | 1 | 2012 | 36 | 0.100 |
Why?
|
Immunohistochemistry | 3 | 2019 | 11069 | 0.100 |
Why?
|
Quantitative Trait Loci | 1 | 2020 | 2112 | 0.100 |
Why?
|
Phytotherapy | 1 | 2014 | 296 | 0.100 |
Why?
|
Hydrochlorothiazide | 1 | 2012 | 94 | 0.100 |
Why?
|
Cryosurgery | 2 | 2021 | 468 | 0.100 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2015 | 246 | 0.100 |
Why?
|
Antirheumatic Agents | 1 | 2022 | 1365 | 0.100 |
Why?
|
Nifedipine | 1 | 2012 | 221 | 0.100 |
Why?
|
Sunscreening Agents | 1 | 2012 | 139 | 0.100 |
Why?
|
Autoimmune Diseases | 1 | 2024 | 2238 | 0.100 |
Why?
|
Electrosurgery | 1 | 2012 | 51 | 0.100 |
Why?
|
Clinical Coding | 1 | 2013 | 181 | 0.100 |
Why?
|
Molecular Targeted Therapy | 2 | 2021 | 2812 | 0.100 |
Why?
|
Child | 10 | 2018 | 80089 | 0.100 |
Why?
|
Drug Utilization | 1 | 2017 | 1186 | 0.090 |
Why?
|
Drug Eruptions | 1 | 2014 | 335 | 0.090 |
Why?
|
Quality of Life | 2 | 2017 | 13359 | 0.090 |
Why?
|
Repressor Proteins | 1 | 2022 | 2985 | 0.090 |
Why?
|
International Classification of Diseases | 2 | 2015 | 912 | 0.090 |
Why?
|
Private Practice | 1 | 2011 | 153 | 0.090 |
Why?
|
Immunity | 1 | 2017 | 994 | 0.090 |
Why?
|
Sensitivity and Specificity | 4 | 2015 | 14649 | 0.090 |
Why?
|
Fees and Charges | 1 | 2011 | 192 | 0.090 |
Why?
|
Basal Cell Nevus Syndrome | 1 | 2010 | 38 | 0.090 |
Why?
|
Marital Status | 1 | 2011 | 425 | 0.090 |
Why?
|
Fetal Blood | 1 | 2017 | 1347 | 0.090 |
Why?
|
Family | 2 | 2011 | 3193 | 0.090 |
Why?
|
Biopsy | 3 | 2013 | 6763 | 0.090 |
Why?
|
Gastrectomy | 1 | 2015 | 671 | 0.080 |
Why?
|
Calcium, Dietary | 1 | 2012 | 529 | 0.080 |
Why?
|
Gene Frequency | 1 | 2017 | 3601 | 0.080 |
Why?
|
Neoplasms, Basal Cell | 1 | 2009 | 31 | 0.080 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2014 | 732 | 0.080 |
Why?
|
Exanthema | 1 | 2014 | 503 | 0.080 |
Why?
|
Patient Education as Topic | 1 | 2020 | 2315 | 0.080 |
Why?
|
Cluster Analysis | 1 | 2016 | 2703 | 0.080 |
Why?
|
Computer-Assisted Instruction | 1 | 2012 | 362 | 0.080 |
Why?
|
Professional Competence | 1 | 2012 | 431 | 0.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2023 | 4010 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6473 | 0.080 |
Why?
|
Motivation | 1 | 2019 | 2003 | 0.080 |
Why?
|
Sex Characteristics | 1 | 2019 | 2637 | 0.080 |
Why?
|
Pulmonary Embolism | 1 | 2022 | 2568 | 0.080 |
Why?
|
Drug Prescriptions | 1 | 2018 | 1669 | 0.080 |
Why?
|
Survival Analysis | 3 | 2016 | 10072 | 0.080 |
Why?
|
Northwestern United States | 1 | 2008 | 20 | 0.080 |
Why?
|
Antibodies, Monoclonal | 2 | 2017 | 9171 | 0.080 |
Why?
|
Disease-Free Survival | 2 | 2016 | 6807 | 0.080 |
Why?
|
Family Relations | 1 | 2010 | 315 | 0.080 |
Why?
|
Longitudinal Studies | 2 | 2018 | 14599 | 0.080 |
Why?
|
Viral Load | 1 | 2017 | 3325 | 0.080 |
Why?
|
Postoperative Hemorrhage | 1 | 2011 | 414 | 0.070 |
Why?
|
Hedgehog Proteins | 1 | 2012 | 768 | 0.070 |
Why?
|
Linear Models | 1 | 2018 | 5866 | 0.070 |
Why?
|
Food | 1 | 2012 | 768 | 0.070 |
Why?
|
Eggs | 1 | 2009 | 182 | 0.070 |
Why?
|
Skin Transplantation | 2 | 2004 | 1083 | 0.070 |
Why?
|
Predictive Value of Tests | 3 | 2013 | 15250 | 0.070 |
Why?
|
Head-Down Tilt | 1 | 2007 | 65 | 0.070 |
Why?
|
Boston | 1 | 2020 | 9313 | 0.070 |
Why?
|
Methotrexate | 1 | 2013 | 1716 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3599 | 0.070 |
Why?
|
Transcription, Genetic | 1 | 2020 | 7583 | 0.070 |
Why?
|
Health Personnel | 2 | 2017 | 3333 | 0.070 |
Why?
|
Sweat Gland Diseases | 1 | 2006 | 12 | 0.070 |
Why?
|
Cause of Death | 1 | 2017 | 3683 | 0.070 |
Why?
|
Torsion Abnormality | 1 | 2007 | 91 | 0.070 |
Why?
|
Psychological Theory | 1 | 2007 | 175 | 0.070 |
Why?
|
Eosinophil-Derived Neurotoxin | 1 | 2006 | 13 | 0.070 |
Why?
|
Eosinophil Major Basic Protein | 1 | 2006 | 14 | 0.070 |
Why?
|
Program Development | 1 | 2012 | 1293 | 0.070 |
Why?
|
Neoplasms | 4 | 2021 | 22131 | 0.070 |
Why?
|
Eccrine Glands | 1 | 2006 | 52 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2012 | 2916 | 0.070 |
Why?
|
Milk | 1 | 2009 | 442 | 0.060 |
Why?
|
Lung Transplantation | 1 | 2015 | 1310 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7390 | 0.060 |
Why?
|
Mupirocin | 1 | 2006 | 55 | 0.060 |
Why?
|
Behavior Therapy | 1 | 2011 | 877 | 0.060 |
Why?
|
Genetic Variation | 1 | 2021 | 6561 | 0.060 |
Why?
|
Algorithms | 4 | 2016 | 14024 | 0.060 |
Why?
|
Fishes | 1 | 2009 | 602 | 0.060 |
Why?
|
Immunotherapy | 1 | 2021 | 4642 | 0.060 |
Why?
|
Genetic Counseling | 1 | 2009 | 627 | 0.060 |
Why?
|
Homeodomain Proteins | 1 | 2015 | 2413 | 0.060 |
Why?
|
Infant | 4 | 2014 | 36157 | 0.060 |
Why?
|
Nutrition Surveys | 1 | 2012 | 1725 | 0.060 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2019 | 4570 | 0.060 |
Why?
|
Body Mass Index | 2 | 2021 | 12942 | 0.060 |
Why?
|
Phylogeny | 2 | 2015 | 2805 | 0.060 |
Why?
|
Multivariate Analysis | 3 | 2016 | 12043 | 0.060 |
Why?
|
Hair | 1 | 2008 | 498 | 0.060 |
Why?
|
Stomach Neoplasms | 1 | 2015 | 1459 | 0.060 |
Why?
|
Infant, Newborn | 3 | 2014 | 26183 | 0.060 |
Why?
|
Faculty, Medical | 1 | 2012 | 1204 | 0.060 |
Why?
|
Acetaminophen | 1 | 2008 | 555 | 0.060 |
Why?
|
Bandages | 1 | 2006 | 269 | 0.060 |
Why?
|
Hamartoma | 1 | 2006 | 236 | 0.060 |
Why?
|
Cervix Uteri | 1 | 2007 | 570 | 0.060 |
Why?
|
Sodium Chloride | 1 | 2006 | 586 | 0.060 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 318 | 0.060 |
Why?
|
Curriculum | 1 | 2017 | 3739 | 0.060 |
Why?
|
Immune Tolerance | 1 | 2012 | 2298 | 0.050 |
Why?
|
Animals | 7 | 2021 | 168202 | 0.050 |
Why?
|
Mortality | 1 | 2015 | 2899 | 0.050 |
Why?
|
Signal Transduction | 2 | 2019 | 23415 | 0.050 |
Why?
|
Arteriovenous Malformations | 1 | 2006 | 396 | 0.050 |
Why?
|
DNA Damage | 1 | 2012 | 2445 | 0.050 |
Why?
|
Energy Metabolism | 1 | 2013 | 2878 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8542 | 0.050 |
Why?
|
Risk Reduction Behavior | 1 | 2009 | 1110 | 0.050 |
Why?
|
Graft Rejection | 1 | 2015 | 4438 | 0.050 |
Why?
|
Genetic Testing | 2 | 2019 | 3533 | 0.050 |
Why?
|
Cyclooxygenase 2 | 1 | 2004 | 596 | 0.050 |
Why?
|
Health Behavior | 2 | 2017 | 2643 | 0.050 |
Why?
|
Disclosure | 1 | 2007 | 747 | 0.050 |
Why?
|
Aspirin | 1 | 2013 | 3127 | 0.050 |
Why?
|
New York | 1 | 2023 | 875 | 0.050 |
Why?
|
Physicians | 1 | 2019 | 4583 | 0.050 |
Why?
|
Education, Medical | 1 | 2012 | 1725 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5430 | 0.050 |
Why?
|
Diclofenac | 1 | 2021 | 68 | 0.050 |
Why?
|
Necrosis | 1 | 2005 | 1610 | 0.040 |
Why?
|
Diagnosis, Differential | 3 | 2007 | 12966 | 0.040 |
Why?
|
Arthritis, Rheumatoid | 1 | 2015 | 3752 | 0.040 |
Why?
|
Mucous Membrane | 1 | 2023 | 659 | 0.040 |
Why?
|
Vaccination | 2 | 2023 | 3370 | 0.040 |
Why?
|
Life Style | 1 | 2012 | 3907 | 0.040 |
Why?
|
Isoenzymes | 1 | 2004 | 1687 | 0.040 |
Why?
|
Surgical Mesh | 1 | 2002 | 311 | 0.040 |
Why?
|
Mutation | 3 | 2019 | 30015 | 0.040 |
Why?
|
Primary Health Care | 2 | 2017 | 4677 | 0.040 |
Why?
|
Patient-Centered Care | 1 | 2009 | 1419 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2018 | 26065 | 0.040 |
Why?
|
Hand | 1 | 2004 | 902 | 0.040 |
Why?
|
Clinical Competence | 1 | 2013 | 4790 | 0.040 |
Why?
|
Keratoacanthoma | 1 | 2017 | 33 | 0.040 |
Why?
|
Delphi Technique | 1 | 2021 | 846 | 0.040 |
Why?
|
Photosensitivity Disorders | 1 | 2017 | 80 | 0.040 |
Why?
|
Cell Size | 1 | 1999 | 624 | 0.040 |
Why?
|
Retinoids | 1 | 2017 | 99 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13383 | 0.040 |
Why?
|
Hair Follicle | 1 | 1999 | 211 | 0.040 |
Why?
|
Antibody Specificity | 1 | 1999 | 1057 | 0.040 |
Why?
|
PUVA Therapy | 1 | 1997 | 101 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6345 | 0.040 |
Why?
|
Time Factors | 3 | 2017 | 39908 | 0.030 |
Why?
|
Communication | 1 | 2010 | 3851 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 1999 | 1703 | 0.030 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7403 | 0.030 |
Why?
|
Infant, Premature | 1 | 2006 | 2107 | 0.030 |
Why?
|
Postoperative Complications | 2 | 2015 | 15609 | 0.030 |
Why?
|
Societies, Medical | 2 | 2018 | 3901 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2023 | 20988 | 0.030 |
Why?
|
Niacinamide | 1 | 2017 | 413 | 0.030 |
Why?
|
Vitamin B Complex | 1 | 2017 | 299 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3268 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2004 | 1878 | 0.030 |
Why?
|
Sampling Studies | 1 | 2016 | 615 | 0.030 |
Why?
|
Environmental Exposure | 1 | 2009 | 4483 | 0.030 |
Why?
|
Public Health | 1 | 2007 | 2671 | 0.030 |
Why?
|
Risk Adjustment | 1 | 2018 | 600 | 0.030 |
Why?
|
Pregnancy Trimester, Second | 1 | 2017 | 730 | 0.030 |
Why?
|
Oncogenes | 1 | 2019 | 1220 | 0.030 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2017 | 645 | 0.030 |
Why?
|
Computers | 1 | 2016 | 591 | 0.030 |
Why?
|
Socioeconomic Factors | 2 | 2021 | 7805 | 0.030 |
Why?
|
Computer User Training | 1 | 2012 | 19 | 0.030 |
Why?
|
Erythema | 1 | 2014 | 262 | 0.030 |
Why?
|
Pregnancy Trimester, First | 1 | 2017 | 908 | 0.030 |
Why?
|
Reimbursement Mechanisms | 1 | 2018 | 667 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2017 | 1784 | 0.030 |
Why?
|
Visual Pathways | 1 | 1996 | 551 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2015 | 11107 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2018 | 1742 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 1999 | 6126 | 0.020 |
Why?
|
Pharmacoepidemiology | 1 | 2015 | 350 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2023 | 8516 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2016 | 1624 | 0.020 |
Why?
|
Papillomavirus Vaccines | 1 | 2017 | 496 | 0.020 |
Why?
|
Washington | 1 | 2012 | 315 | 0.020 |
Why?
|
RNA, Viral | 1 | 2019 | 2838 | 0.020 |
Why?
|
Drugs, Generic | 1 | 2016 | 448 | 0.020 |
Why?
|
Primary Prevention | 1 | 2018 | 1185 | 0.020 |
Why?
|
Phototherapy | 1 | 2013 | 368 | 0.020 |
Why?
|
Pattern Recognition, Visual | 1 | 1996 | 824 | 0.020 |
Why?
|
Antifungal Agents | 1 | 2015 | 753 | 0.020 |
Why?
|
Ibuprofen | 1 | 2012 | 229 | 0.020 |
Why?
|
Codon | 1 | 2012 | 600 | 0.020 |
Why?
|
Decision Making | 1 | 2024 | 3919 | 0.020 |
Why?
|
Medical Records Systems, Computerized | 1 | 2016 | 1191 | 0.020 |
Why?
|
Research | 1 | 2018 | 1977 | 0.020 |
Why?
|
Hospitalization | 2 | 2023 | 10708 | 0.020 |
Why?
|
Photic Stimulation | 1 | 1996 | 1987 | 0.020 |
Why?
|
Coccidioidomycosis | 1 | 1970 | 37 | 0.020 |
Why?
|
Histoplasmosis | 1 | 1970 | 63 | 0.020 |
Why?
|
Prenatal Care | 1 | 2017 | 1140 | 0.020 |
Why?
|
Michigan | 1 | 2009 | 339 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2018 | 2821 | 0.020 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 2008 | 66 | 0.020 |
Why?
|
Disease Management | 1 | 2018 | 2506 | 0.020 |
Why?
|
Skin Tests | 1 | 1970 | 637 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2004 | 7847 | 0.020 |
Why?
|
Gene Expression | 1 | 2020 | 7569 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 4910 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2015 | 1852 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2011 | 1185 | 0.020 |
Why?
|
Mouth Mucosa | 1 | 2008 | 432 | 0.020 |
Why?
|
Psychology | 1 | 2007 | 356 | 0.020 |
Why?
|
Family Characteristics | 1 | 2010 | 992 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2001 | 7995 | 0.020 |
Why?
|
Vaginal Smears | 1 | 2007 | 499 | 0.010 |
Why?
|
Graft Survival | 1 | 2015 | 3814 | 0.010 |
Why?
|
Mice | 3 | 2021 | 81368 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2015 | 5239 | 0.010 |
Why?
|
Postmenopause | 1 | 2013 | 2511 | 0.010 |
Why?
|
Health Expenditures | 1 | 2016 | 2363 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8652 | 0.010 |
Why?
|
Regression Analysis | 1 | 2012 | 6339 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 11735 | 0.010 |
Why?
|
Medicaid | 1 | 2016 | 2814 | 0.010 |
Why?
|
Lipids | 1 | 2013 | 3332 | 0.010 |
Why?
|
Varicose Ulcer | 1 | 2002 | 55 | 0.010 |
Why?
|
Precancerous Conditions | 1 | 2007 | 982 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2018 | 20077 | 0.010 |
Why?
|
Health Surveys | 1 | 1970 | 4036 | 0.010 |
Why?
|
Blood Glucose | 1 | 2013 | 6390 | 0.010 |
Why?
|
Diabetic Foot | 1 | 2002 | 379 | 0.010 |
Why?
|
Medicare | 1 | 2016 | 6774 | 0.010 |
Why?
|
Blood Pressure | 1 | 2013 | 8473 | 0.010 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 1997 | 329 | 0.010 |
Why?
|
Pregnancy | 1 | 2017 | 29869 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2011 | 10203 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2012 | 6927 | 0.010 |
Why?
|
Wound Healing | 1 | 2002 | 2802 | 0.010 |
Why?
|
Histoplasmin | 1 | 1970 | 2 | 0.010 |
Why?
|
Mass Chest X-Ray | 1 | 1970 | 18 | 0.010 |
Why?
|
Coccidioides | 1 | 1970 | 18 | 0.010 |
Why?
|
Histoplasma | 1 | 1970 | 39 | 0.010 |
Why?
|
Soil Microbiology | 1 | 1970 | 88 | 0.010 |
Why?
|
Tuberculin Test | 1 | 1970 | 206 | 0.010 |
Why?
|
Climate | 1 | 1970 | 147 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 1996 | 36401 | 0.000 |
Why?
|
Blood Cell Count | 1 | 1970 | 397 | 0.000 |
Why?
|
Visual Cortex | 1 | 1996 | 1105 | 0.000 |
Why?
|
Polymerase Chain Reaction | 1 | 1997 | 6074 | 0.000 |
Why?
|
Occupations | 1 | 1970 | 516 | 0.000 |
Why?
|
Sputum | 1 | 1970 | 506 | 0.000 |
Why?
|
Iran | 1 | 1970 | 737 | 0.000 |
Why?
|
Antigens | 1 | 1970 | 1441 | 0.000 |
Why?
|
Brain Mapping | 1 | 1996 | 6635 | 0.000 |
Why?
|
Rural Population | 1 | 1970 | 2277 | 0.000 |
Why?
|